House Appropriations Committee approves fiscal 2018 Labor-HHS spending bill

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The House Appropriations Committee marked up the fiscal 2018 Labor-HHS funding bill with a vote of 28-22 on July 19.

The bill includes a $1.1 billion increase for NIH, a $82 million funding boost for the NCI, and preserves the individual programs and current funding levels for the Centers for Disease Control and Prevention cancer screening and early detection programs. This version of the bill eliminates funding for the Affordable Care Act and the Family Planning (Title X) Program (The Cancer Letter, July 14).

“United for Medical Research applauds the increase to the budget for NIH contained in the Labor, Health and Human Services, and Education funding bill approved by the House Appropriations Committee yesterday,” UMR President Lizbet Boroughs said in a statement. “We are deeply appreciative of Subcommittee Chairman Tom Cole’s unwavering support for boosting funding for medical research.

“We also want to thank Ranking Member Rosa DeLauro and full Committee Chairman Rodney Frelinghuysen and Ranking Member Nita Lowey for making funding for medical research a high priority in this bill. We look forward to working with the Senate on its Labor-HHS funding bill and with the full Congress to ensure a 2018 budget solution that enables increased funding for the NIH and the medical research initiatives called for by the 21st Century Cures Act.”

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login